PARIS--(Marketwire - November 08, 2012) - Mauna Kea Technologies (NYSE Euronext: MKEA), leader in the optical biopsy market and developer of Cellvizio®, the fastest way to see cancer, today announced that Sacha Loiseau, PhD, Founder and CEO will present at the 9th Annual Lazard Healthcare Conference taking place on November 13-14 in New York City. Mr. Loiseau's presentation is scheduled for Wednesday, November 14, 2012 at 3:30 pm ET.
As previously reported, Mauna Kea Technologies achieved a 91 percent increase in sales during the first nine months of 2012 compared to the same period in 2011. The Cellvizio system now is available in more than 45 countries worldwide and has received important regulatory clearances in recent months in Canada, the Russian Federation and Brazil. The company recently announced the European launch of the AQ Flex™ 19, the first in a new line of Cellvizio miniprobes to provide real-time, cellular-level visualization inside pancreatic cysts during needle-based procedures. In the United States, the American Medical Association (AMA) approved the creation of three Class I CPT® codes for reimbursement of Cellvizio procedures in the upper gastrointestinal tract and use in pathology. These codes will influence insurance coverage and reimbursement with Medicare and private US insurance programs once they go into effect on January 1, 2013. In addition, more than 140 peer-reviewed publications underscoring the value of Cellvizio have been published to date.
To access a live webcast of this presentation, visit http://www.maunakea-corp.com/. A replay will be available for two weeks at the above-referenced website.
About Mauna Kea Technologies
Mauna Kea Technologies is a global medical device company dedicated to the advent of optical biopsy. The company researches, develops and markets innovative tools to visualize and detect cellular abnormalities during endoscopic procedures. Its flagship product, Cellvizio®, a probe-based Confocal Laser Endomicroscopy (pCLE) system, provides physicians and researchers high-resolution cellular views of tissue inside the body. Large, international, multicenter clinical trials have demonstrated Cellvizio's ability to help physicians more accurately detect early forms of disease and make treatment decisions immediately. Designed to improve patient outcomes and reduce costs within a hospital, Cellvizio can be used with almost any endoscope. Cellvizio has 510(k) clearance from the U.S. Food and Drug Administration and the European CE-Mark for use in the GI tract, biliary and pancreatic ducts and lungs.
For more information about Mauna Kea Technologies, visit www.maunakeatech.com.